Tang Prize in Biopharmaceutical Science Honors Three Pioneers of CAR-T Therapy, Ushering in a New Era of 'Living Drugs'
NQ Score
49/100
N1 Content Completeness
5
AI Summary (NQ-processed)
The 2026 Tang Prize in Biopharmaceutical Science has been awarded to Steven A. Rosenberg, Michel Sadelain, and Carl H. June for their groundbreaking work in developing CAR-T cell therapy. By harnessing patients' own immune cells to fight cancer, they have pioneered a revolutionary 'living drug' approach to cancer treatment.
AI Analysis
Frequently Asked Questions
- Q: What is the Tang Prize in Biopharmaceutical Science?
- A: An international award honoring breakthroughs in treating diseases like cancer.
- Q: Who was the first CAR-T patient?
- A: Emily Whitehead, a young girl treated in 2012 for acute lymphoblastic leukemia.
- Q: Which cancers respond to CAR-T therapy?
- A: Most effective in B-cell leukemias and lymphomas.
- Q: How does the Tang Prize differ from the Nobel Prize?
- A: It includes unique categories like Sinology and Rule of Law, and is Asia-based.
- Q: Future applications of CAR-T?
- A: Being studied for heart repair, anti-aging, and autoimmune diseases.